Form 4: Shattuck Labs Officer's Stock Option Grant and Share Sale

Shattuck Labs' General Counsel Stephen Stout reported the acquisition of 351,400 stock options and the disposition of 4,153 common shares on January 10, 2026.

Summary

• Stephen Stout, General Counsel, Corporate Secretary, and Chief Ethics and Compliance Officer of Shattuck Labs, Inc., reported transactions on January 10, 2026.
• Acquired 351,400 stock options with an exercise price of $4.75 per share, expiring on January 10, 2036.
• The options vest over time: one-quarter on January 10, 2027, and the remainder in equal monthly installments through January 10, 2030, contingent on continued service.
• Disposed of 4,153 shares of common stock at a price of $4.75 per share. This transaction code 'F' typically indicates shares withheld for tax purposes related to equity awards.
• Following these transactions, Stout directly beneficially owns 82,122 shares of common stock and 351,400 stock options.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving an equity grant and a tax-related share disposition, which are neutral events in terms of immediate company performance or outlook.

Positives

• The grant of 351,400 stock options to a key officer, Stephen Stout, aligns his interests with long-term company performance.

Negatives

• The disposition of 4,153 common shares, likely for tax withholding, reduces direct share ownership, though it is a common practice.

Future Outlook

The filing details a vesting schedule for newly granted stock options, indicating a long-term incentive structure for the reporting person, contingent on continued service to the Issuer through January 10, 2030.

Industry Context

This Form 4 reflects a routine insider transaction, common in the biotechnology industry, where equity grants are a standard component of executive compensation packages designed to align management incentives with shareholder value creation over the long term.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard practice for executive compensation in the biotech sector, similar to incentive structures seen at companies like Moderna or BioNTech, aiming to retain key talent and incentivize long-term performance.
• The disposition of shares for tax purposes is also a common occurrence when equity awards vest or are exercised.

Stakeholder Impact

• Shareholders: The grant of options to a key officer aligns management's long-term interests with shareholder value. The disposition of shares for tax purposes is a minor, routine event.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in key leadership roles.

Next Steps

• Continued vesting of 351,400 stock options, with the next significant vesting event on January 10, 2027.
• Stephen Stout's continued service to Shattuck Labs, Inc. is required for the options to vest fully.

Key Dates

Keywords

Shattuck Labs, STTK, Stephen Stout, Form 4, Insider Trading, Stock Options, Common Stock, Equity Grant, Vesting Schedule, Officer Transaction